Human TRAIL / CD253 ELISA Kit PicoKine® EK0532 from BosterBio

Product Specs
ItemHuman TRAIL / CD253 ELISA Kit PicoKine®
CompanyBosterBio
Price $499.00Supplier Page View Company Product Page
Catalog NumberEK0532
Quantity96 wells/kit, with removable strips
Detection Range15.6 pg/ml - 1,000 pg/ml
ReactivityHuman
Sensitivity<1 pg/ml
NCBI Gene AliasesTNLG6A, TL2, CD253, TANCR, TRAIL, Apo-2L, APO2L
Sample Typecell culture supernatants, cell lysates, serum, plasma (heparin, EDTA) and saliva
Gene NameTNFSF10
ImmunogenExpression system for standard: NS0; Immunogen sequence: T95-G281
ApplicationsELISA
Anticoagulantheparin or EDTA
Molecular Weight32509 MW
Assay Time15-25min
Research AreaApoptosis,Atherosclerosis,Cancer,Cardiovascular,Cell Biology,Cell Death,Invasion/Microenvironment,Receptors
StorageStore at 4℃ for 6 months, at -20℃ for 12 months. Avoid multiple freeze-thaw cycles (Ships with gel ice, can store for up to 3 days in room temperature. Freeze upon receiving.)
Detection TargetTumor necrosis factor ligand superfamily member 10

3942 B Valley Ave.

Pleasanton, CA 94566

United States

Phone: (888) 466-3604
Fax: (925)215-2184

Email: support@bosterbio.com

(1) A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T CellsInternational journal of molecular sciencesSeptember 30, 2024Nguyen HTX, Song Y, Kumar S, Liang FS.

(4) Transforming Growth Factor-β Promotes Homing and Therapeutic Efficacy of Human Mesenchymal Stem Cells to GlioblastomaJournal of neuropathology and experimental neurologyApril 1, 2019Li M, Zeng L, Liu S, Dangelmajer S, Kahlert UD, Huang H, Han Y, Chi X, Zhu M, Lei T.

(5) Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant gliomaStem cell research & therapyMarch 12, 2019Li M, Sun S, Dangelmajer S, Zhang Q, Wang J, Hu F, Dong F, Kahlert UD, Zhu M, Lei T.

(7) A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killingOncotargetSeptember 22, 2015Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, et al.

(10) Serum TRAIL levels in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. A pilot studyEuropean journal of gynaecological oncologyJanuary 1, 2011A Gasowska-Bodnar, L Bodnar, A Synowiec, M Jerzak, G Wcislo, M Smoter, C Szczylik, W Baranowski

Human TRAIL / CD253 ELISA Kit PicoKine